Respiratory syncytial virus (RSV) infections were associated with significantly increased risk for complications beyond ...

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

Test positivity for common cold coronaviruses significantly declined following widespread SARS-CoV-2 infection and COVID-19 ...